2021
Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients
Cecchini M, Quah C, Liu S, Woloski R, Udyavar A, Giannakis M. Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients. Cancer Research 2021, 81: ct129-ct129. DOI: 10.1158/1538-7445.am2021-ct129.Peer-Reviewed Original ResearchModified FOLFOX-6Metastatic colorectal cancerFOLFOX-6American Association for Cancer Research annual meetingsColorectal cancerAnti-tumor immune responseAssociated with disease controlDying cancer cellsMCRC ptsAdenosine receptor blockadeOpen-label studyRelease of ATPAntagonists of A2ARMedian PFSPretreated ptsReceptor blockadeEligible ptsOrally onceExtracellular adenosineA2B receptorsImmune cellsChemotherapeutic agentsTherapeutic efficacyClinical activityImmune responseARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).
Cecchini M, Krishnan K, Giafis N, Scott J, Quah C, Bendell J. ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2021, 39: tps150-tps150. DOI: 10.1200/jco.2021.39.3_suppl.tps150.Peer-Reviewed Original ResearchMetastatic colorectal cancerStandard-of-careStandard-of-care armMFOLFOX-6Cohort BCohort AActivation of effector T cellsModified 5-fluorouracilTreated with FOLFOXDying cancer cellsDose-escalation studyEffector T cellsPhase Ib/II studyAdenosine receptor blockadeAdenosine receptor antagonistPhase 1b/2Escalation studyCurative intentReceptor blockadeOpen-labelImmunosuppressive adenosineCombination therapyPrimary endpointReceptor antagonistCohort C
2020
Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)
Cecchini M, Modiano M, Braiteh F, Gardner O, Gilbert H, DiRenzo D, Seitz L, Walters M, Yin F, Woloski R, Paoloni M, Chung K. Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3). Cancer Research 2020, 80: lb-387-lb-387. DOI: 10.1158/1538-7445.am2020-lb-387.Peer-Reviewed Original ResearchModified FOLFOX-6Metastatic colorectal cancerAdverse eventsPhase 1bFOLFOX-6Stable diseaseColorectal cancerAnti-tumor immune responseECOG performance status 0Recommended doseAssociated with disease controlExploratory biomarker analysesTumor shrinkage >Disease control rateDying cancer cellsGrade 3 AEsPerformance status 0Dose-escalation studyAdenosine receptor blockadeOpen-label studyAmerican Association for Cancer ResearchAdenosine receptor antagonistRelease of ATPNext gene sequencingAdenosine axis